T1	Participants 89 145	patients with locally advanced resectable rectal cancer.
T2	Participants 363 394	Patients with stage II/III LARC
T3	Participants 873 933	Thirty-seven patients were eligible for safety and efficacy.
T4	Participants 934 1026	TMN staging at baseline was: T4N2, 11%; T3N2, 40%; T2N2, 3%; T3N1, 35%; T2N1, 3% and T3N0 8%
T5	Participants 1687 1716	patients with resectable LARC
